 Therapies targeting specific tumor pathways are easy to enter the clinic. To monitor molecular changes , cellular processes , and tumor microenvironment , molecular imaging is becoming the key technology for personalized medicine because of its high efficacy and low side effects. Thyroid cancer is the most common endocrine malignancy , and its theranostic radioiodine has been widely used to diagnose or treat differentiated thyroid cancer. This article summarizes recent development of molecular imaging in thyroid cancer , which may accelerate the development of personalized thyroid cancer therapy.